AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Ipca Laboratories Ltd. Director's Dealing 2024

Dec 19, 2024

61700_rns_2024-12-19_df6b1fa3-4630-4cb7-97c7-c86a52ded97b.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

December 19, 2024

==> picture [112 x 49] intentionally omitted <==

THRU ONLINE FILING

National Stock Exchange India Limited, Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra – (East). Mumbai-400051. Scrip Code : IPCALAB

Kind Attention : Mr. Binoy Yohannan, Associate Vice President, Surveillance

Dear Sir,

Sub: Increase in Volume

We refer to your letter under Ref. No. : NSE/CM/Survelliance/15105 dt. December 18, 2024 regarding your noticing significant increase in the trading volume of Company’s securities across exchanges.

In this regard, we wish to inform you that the Company has no information or announcement (including impending announcement) which in our opinion will have a bearing on the price / volume behavior in the Company’s scrip.

With respect to the traded volume of the Company’s scrip, we wish to inform you that one of the Promoter / Promoter Group shareholder of the Company, Mrs. Usha M. Chandurkar has sold 40,00,000 equity shares of the Company on BSE on 18[th] December, 2024. The necessary disclosure in respect of this sale transaction has been given by the Company / Seller to the stock exchanges today under the relevant provisions of the SEBI (PIT) Regulations and SEBI (SAST) Regulations.